VIENNA—The bone microenvironment was regarded as a worthy target for breast cancer treatment in comments at the St Gallen Breast Cancer Conference from Michael Gnant MD, a Professor and Director of the Medical University of Vienna, who gave Oncology Times reporter Sarah Maxwell the latest data on the clinical potential of bone-directed therapies.
You may also like...
ASCO Audio Journal of Oncology – June 1st, 2006 – In the company of Gordon McVie 30 May, 2006 Enzalutamide in metastatic castration resistant prostate cancer: over 75s benefit too 24 Mar, 2013 BRCA-deficient cancers respond to combination of two experimental drugs 24 Apr, 2013 Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer 27 Oct, 2018
- Previous story BCL-2: A New Therapeutic Target in Estrogen-Receptor Positive Breast Cancer
- Next story Breast Cancer Prognostic Implications of Obesity and Insulin Resistance
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014